Industry News

Abeona Therapeutics, Inc., a leading clinical-stage biopharmaceutical company focused on delivering gene and plasma-therapies for life-threatening rare..."/>
Abeona Therapeutics Announces European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported..."/>
Agios Reports Second Quarter 2016 Financial Results
Inspyr Therapeutics, Inc., a clinical-stage biotechnology company developing novel prodrug therapeutics for the treatment of cancer, announces that Christopher Lowe has been appointed President and Chief Executive Officer, and as a member of the Company’ s Board of Directors. Lowe brings to Inspyr Therapeutics more than 15 years of executive management experience in life sciences as Chief Executive Officer, Chief Financial Officer and Chief Business Officer,..."/>
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, will provide a corporate update and report financial results for the second quarter ended June 30, 2016 before the NASDAQ market opens on Thursday, August 11, 2016.. The company will not be conducting a conference call in conjunction with this earnings release. Clearside Biomedical, Inc.,..."/>
Clearside Biomedical, Inc. to Report Second Quarter 2016 Financial Results
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, today announced that Kei Kishimoto, Ph.D., CSO, will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2016, at 9:30 am EDT at the InterContinental in Boston.. A live webcast will be available on the Investors& Media section of the Selecta website at www.selectabio.com. An archived replay will be..."/>
Selecta Biosciences to Present at Canaccord Genuity Growth Conference
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex ®, a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2016.. "In the second quarter we completed enrollment in the OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials of Locilex in patients with mild infections of diabetic foot ulcers and expect..."/>
Dipexium Pharmaceuticals Reports Second Quarter 2016 Financial Results
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will present at the 36th Annual Canaccord| Genuity Growth Conference on August 10 th, 2016, in Boston, Massachusetts. The company is scheduled to present at 1:00 p.m. EDT.."/>
Akari Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference
Parnell Pharmaceuticals Holdings Ltd, a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced financial results for the first six months of 2016 including; strong revenue growth of 67%; the commencement of contract manufacturing revenues; the upcoming US launch of two new companion animal products, Luminous™ and Reviderm™; and the..."/>
Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2016
Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2016.. On August 2, Teva completed the Actavis Generics acquisition On August 3, Teva agreed to acquire Anda for $500 million. “We are pleased with our performance this quarter and the steps we are taking to transform our business, notably the recent completion of our acquisition of Actavis Generics and the proposed purchase of Anda Inc. We have brought together two leading..."/>
Teva Reports Second Quarter 2016 Results
ZIOPHARM Oncology, Inc., a biopharmaceutical company focused on new immunotherapies, today announced the publication of data highlighting the benefits of using the non-viral Sleeping Beauty system to genetically modify..."/>
First-In-Human Trials using Non-Viral Sleeping Beauty System to Express CD19-Specific CAR in T cells Published in Journal of Clinical Investigation
Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and..."/>
Paratek Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial and Operating Results
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the quarter ended June 30, 2016, and provided a corporate update.. Second Quarter 2016 Financial Results. Intra-Cellular Therapies reported a net loss of $30.8 million, or $0.71 per share, for the second quarter of 2016 compared to a net loss of $21.5 million, or $0.61 per..."/>
Intra-Cellular Therapies Reports Second Quarter 2016 Financial Results and Provides Corporate Update
ContraFect Corporation, a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announces that it has been granted Small and Medium Enterprise designation by the European Medicines Agency. The SME designation was established by EMA to promote innovation and the development of new medicinal products by smaller companies."/>
ContraFect Receives Designation as a Small and Medium Enterprise by the European Medicines Agency
NuVasive, Inc., a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced that the U.S. Centers for Medicare and Medicaid Services has granted a new technology add-on payment for magnetically controlled growth rods. For a technology to qualify for an NTAP in the inpatient setting, the solution must demonstrate a substantial clinical improvement relative to..."/>
NuVasive Secures CMS Add-On Payment for Innovative MAGEC System
OTC Markets Group Inc., operator of financial markets for 10,000 U.S. and global securities, today announced Stereotaxis, Inc., a healthcare technology and innovation leader focused on the development of robotic cardiology instrument navigation systems, has qualified to trade on the OTCQX ® Best Market. Stereotaxis, Inc. previously traded on NASDAQ. Stereotaxis, Inc. begins trading today on OTCQX under the symbol "STXS.""/>
OTC Markets Group Welcomes Stereotaxis, Inc. to OTCQX
BioDelivery Sciences International, Inc. announced that it has reached its target number of subjects to be randomized in its multi-center, double-blind, placebo-controlled Phase 2 b study assessing the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with painful diabetic neuropathy. Based on the timing of randomization of the last patient, BDSI now expects topline results of the study will be available by..."/>
BioDelivery Sciences Announces Randomization Target Reached in Clinical Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
Akorn Provides Second Quarter 2016 Results
Lexicon Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2016 and provided an overview of key milestones for the company's lead drug candidates. "We enter the second half of the year with significant momentum, with both telotristat etiprate and sotagliflozin," said Lexicon President and Chief Executive Officer, Lonnel Coats. "We are looking forward to our upcoming PDUFA date of November 30..."/>
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Second Quarter Financial Results
Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today reported its financial results for the second quarter ended June 30, 2016.. "We are pleased that dosing of patients has started in the Phase 1 trial of CA-170, the first oral, small molecule immune checkpoint inhibitor targeting PD-L1 and VISTA pathways from our collaboration..."/>
Curis Reports Second Quarter 2016 Financial Results
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months ended June 30, 2016.. "EnteroMedics continues to build momentum into the second half of the year, with a four-fold increase in vBloc procedures seen in the second quarter over the first quarter, all while maintaining..."/>
EnteroMedics Reports Second Quarter 2016 Financial Results
Syneron Medical Ltd., a leading global aesthetic device company, today announced financial results for the three month period ended June 30, 2016.. Second Quarter 2016 Non-GAAP 2 Financial Highlights:. Revenue of $75.0 million, up 2.0% year-over-year, with 11.5% international growth and a 14% decline in North America Emerging products revenue, which represent the Company's strategic growth drivers, grew 46% year-over-year, primarily..."/>
Syneron Medical Reports Second Quarter 2016 Revenue of $75.0 Million and Non-GAAP EPS of $0.09
Trevena, Inc., a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced financial results for the quarter ended June 30, 2016 and provided an update regarding its ongoing clinical programs. “This quarter marked an important milestone for the company’ s oliceridine..."/>
Trevena Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of highly innovative..."/>
Acceleron Pharma Reports Second Quarter 2016 Financial and Operational Results

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary737 Articles
Information Technology690 Articles
Financials569 Articles
Health Care406 Articles
Industrials397 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.